178 related articles for article (PubMed ID: 36476331)
1. Influence of progestin-only hormonal use on hepatocellular adenomas: A retrospective cohort study.
Qureshy Z; Lokken RP; Kakar S; Grab J; Mehta N; Sarkar M
Contraception; 2023 Mar; 119():109915. PubMed ID: 36476331
[TBL] [Abstract][Full Text] [Related]
2. Exogenous progestins and breast cancer.
Stanford JL; Thomas DB
Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
[TBL] [Abstract][Full Text] [Related]
3. Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation.
Demory A; Péron JM; Calderaro J; Selves J; Mokrane FZ; Amaddeo G; Paradis V; Ziol M; Sutter O; Blaise L; Ganne-Carrié N; Vilgrain V; Cauchy F; Zucman-Rossi J; Ronot M; Nault JC
Hepatology; 2023 Feb; 77(2):430-442. PubMed ID: 35980227
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral contraceptive progestins on serum copper concentration.
Berg G; Kohlmeier L; Brenner H
Eur J Clin Nutr; 1998 Oct; 52(10):711-5. PubMed ID: 9805216
[TBL] [Abstract][Full Text] [Related]
6. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
7. Progestogens in cardiovascular diseases: an introduction to the epidemiologic data.
Mann JI
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):752-7. PubMed ID: 7065056
[TBL] [Abstract][Full Text] [Related]
8. Contraceptive Steroids, age, and the cardiovascular system.
Plunkett ER
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):747-51. PubMed ID: 7065055
[TBL] [Abstract][Full Text] [Related]
9. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma.
Gordon SC; Reddy KR; Livingstone AS; Jeffers LJ; Schiff ER
Ann Intern Med; 1986 Oct; 105(4):547-9. PubMed ID: 3019201
[TBL] [Abstract][Full Text] [Related]
10. Role of oral contraceptives in the growth of a multilobular adenoma associated with a hepatocellular carcinoma in a young woman.
Perret AG; Mosnier JF; Porcheron J; Cuilleron M; Berthoux P; Boucheron S; Audigier JC
J Hepatol; 1996 Dec; 25(6):976-9. PubMed ID: 9007729
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
[TBL] [Abstract][Full Text] [Related]
12. The formulation of oral contraceptives: does the amount of estrogen make any clinical difference?
Speroff L
Johns Hopkins Med J; 1982 May; 150(5):170-6. PubMed ID: 7043035
[TBL] [Abstract][Full Text] [Related]
13. [Liver tumors in women using oral hormonal contraceptives].
Rabe T; Feldmann K; Grunwald K; Runnebaum B
Zentralbl Gynakol; 1995; 117(3):153-6. PubMed ID: 7740850
[TBL] [Abstract][Full Text] [Related]
14. The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives.
Shulman LP
Am J Obstet Gynecol; 2011 Oct; 205(4 Suppl):S9-13. PubMed ID: 21961825
[TBL] [Abstract][Full Text] [Related]
15. Not All Hepatocellular Adenomas are Caused by the Hormonal Oral Contraceptive.
Rajendiran G
S D Med; 2021 Jul; 74(7):302-303. PubMed ID: 34449989
[TBL] [Abstract][Full Text] [Related]
16. Hormonal contraception and lactation.
Kelsey JJ
J Hum Lact; 1996 Dec; 12(4):315-8. PubMed ID: 9025449
[TBL] [Abstract][Full Text] [Related]
17. Systemic hormonal contraception and risk of venous thromboembolism.
Heikinheimo O; Toffol E; Partonen T; But A; Latvala A; Haukka J
Acta Obstet Gynecol Scand; 2022 Aug; 101(8):846-855. PubMed ID: 35633036
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
Crook D; Godsland IF; Wynn V
Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
[TBL] [Abstract][Full Text] [Related]
19. [Hormonal contraception].
Van Cauwenberge JR
Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
[TBL] [Abstract][Full Text] [Related]
20. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
